<DOC>
	<DOCNO>NCT01856218</DOCNO>
	<brief_summary>UX003-CL201 open-label Phase 1/2 study ass safety , efficacy , dose UX003 MPS 7 subject via IV administration every week ( QOW ) 36 week additional 36 week optional continuation period . Up 5 subject , 5 30 year age inclusive , enrol treat UX003 . The initial 12-week treatment period follow 24-week force dose titration period ass optimal dose . Subjects complete initial treatment force dose titration period continue treatment 36 week continuation period</brief_summary>
	<brief_title>An Open-Label Phase 1/2 Study Assess Safety , Efficacy Dose Study Drug UX003 Recombinant Human Beta-glucuronidase ( rhGUS ) Enzyme Replacement Therapy Patients With MPS 7</brief_title>
	<detailed_description />
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<criteria>Confirmed diagnosis MPS 7 base leukocyte fibroblast glucuronidase enzyme assay genetic test confirm diagnosis . Elevated uGAG excretion minimum 2fold normal . Between 5 30 year age , inclusive ( approximately two subject age 2030 year ) . Willing able provide write , sign informed consent , case subject age 18 ( 16 year , depend region ) , provide write assent ( require ) write informed consent legally authorize representative nature study explain , prior researchrelated procedure . Sexually active subject must willing use acceptable method contraception participate study . Females childbearing potential must negative pregnancy test Screening willing additional pregnancy test study . Females consider childbearing potential include tubal ligation least one year prior Screening , total hysterectomy . Has undergone successful bone marrow stem cell transplant degree detectable chimaerism donor cell . Any known hypersensitivity rhGUS excipients , judgment Investigator , place subject increase risk adverse effect . Pregnant breastfeed Screening plan become pregnant ( self partner ) time study . Use investigational product ( drug device combination ) within 30 day prior Screening , requirement investigational agent prior completion schedule study assessment time study . Has condition severity acuity , opinion Investigator , warrant immediate surgical intervention treatment may allow safe study participation . Has concurrent disease condition , view Investigator , place subject high risk poor treatment compliance complete study , would interfere study participation affect safety .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Mucopolysaccharidosis type 7 , MPS 7 , Sly syndrome , enzyme replacement therapy , rare disease , lysosomal storage disease , metabolic disorder</keyword>
</DOC>